Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 26, 2021; 9(33): 10172-10179
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10172
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10172
Table 3 Changes in hemoglobin, creatinine and C-reactive protein levels over time
Time | Hb in g/L | t | P value | Cre in mol/L | t | P value | CRP in mg/L | t | P value |
Baseline | 114.82 ± 20.45 | 807.43 ± 254.64 | 8.60 ± 16.76 | ||||||
Week 4 | 109.69 ± 19.78 | 1.530 | 0.131 | 749.67 ± 398.06 | 1.062 | 0.292 | 7.13 ± 10.71 | 0.642 | 0.523 |
Week 12 | 111.47 ± 21.11 | 0.967 | 0.337 | 586.40 ± 358.51 | 4.326 | 0.000 | 7.72 ± 4.98 | 0.486 | 0.629 |
Week 24 | 116.21 ± 23.50 | 0.380 | 0.705 | 803.27 ± 192.31 | 0.112 | 0.911 | 8.23 ± 14.82 | 0.206 | 0.838 |
- Citation: Chen X, Zhao F, Pan WJ, Di JM, Xie WN, Yuan L, Liu Z. Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits. World J Clin Cases 2021; 9(33): 10172-10179
- URL: https://www.wjgnet.com/2307-8960/full/v9/i33/10172.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i33.10172